Helicobacter Pylori Non-Invasive Testing Market
Helicobacter Pylori Non-Invasive Testing Market Study by Serology Tests, Stool Antigen Tests, and Urea Breath Tests from 2023 to 2033
Analysis of Helicobacter Pylori Non-Invasive Testing Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Helicobacter Pylori Non-Invasive Testing Market Outlook (2023 to 2033)
Expanding at a CAGR of 4.8%, the global helicobacter pylori non-invasive testing market is forecasted to increase from a valuation of US$ 500 million in 2023 to US$ 800 million by the end of 2033. Only urea breath tests offer accuracy in determining whether helicobacter pylori infection is active or eradicated.
Helicobacter pylori infection, or H. pylori, is the most prevalent bacterial infection, affecting the digestive tract and inner stomach lining. Helicobacter pylori infection is the most prominent cause of dyspepsia, peptic ulcers, and gastric adenocarcinoma.
Helicobacter pylori can also be found in persons who have no symptoms but are at risk for developing these disorders. Helicobacter pylori non-invasive tests are used to assist identify whether H. pylori is the root of these issues.
Since helicobacter pylori infection is typically asymptomatic, the majority of infected individuals are unaware of their condition. Helicobacter pylori Infections are more likely to occur in children.
Patients who have peptic ulcers caused by helicobacter pylori typically experience symptoms such as nausea, vomiting, loss of appetite, and persistent burping. Peptic ulcers can occasionally cause serious side effects such as blockage in the stomach lining, internal bleeding, or perforation.
The adoption of non-invasive tests for diagnosing helicobacter pylori infection and subsequent treatment is rising among healthcare professionals. The availability of new and advanced non-invasive tests such as real-time PCR and chemiluminescence immunoassay (CLIA) is anticipated to boost market growth.
The accuracy and sensitivity of these approaches have improved as a result of new developments in helicobacter pylori detection techniques during the past few years. The demand for these techniques has expanded as a result of their greater acceptance among healthcare practitioners.
Non-invasive tests are preferred for helicobacter pylori infection testing by both patients and healthcare professionals worldwide due to the rapid turnaround time for test results, improved patient compliance, and less discomfort often associated with invasive procedures. These tests are also highly accurate and specific, which helps in making the right diagnosis of helicobacter pylori infection. In comparison to invasive endoscopic alternatives, non-invasive diagnostics are more affordable.
One of the main causes of the spread of helicobacter pylori infections is overcrowding. Other important causes include poor sanitation, poor diet, bad personal hygiene, and unhygienic conditions. One of the factors driving market expansion is the rise in awareness of this infection among the general public worldwide. Growing public awareness of the diagnosis of helicobacter pylori, and new product introductions are boosting market growth.
Report Attributes |
Details |
|
H. Pylori Non-Invasive Testing Market Size (2023) |
US$ 500 Million |
|
Projected Market Value (2033) |
US$ 800 Million |
|
Global Market Growth Rate (2023 to 2033) |
4.8% CAGR |
|
Market Share of Urea Breath Tests |
50% |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why is Helicobacter Pylori Non-Invasive Testing Gaining High Prominence Worldwide?
“Growing Prevalence of Gastric and Duodenal Illnesses”
Rising prevalence of gastric and duodenal illnesses is driving the demand for helicobacter pylori non-invasive testing. Gastric cancer and peptic ulcer disease are both deeply influenced by helicobacter pylori infection, which is generally asymptomatic.
Non-invasive testing systems are typically used as the first line of treatment for helicobacter pylori infections. The market is growing due to the popularity of the urea breath test (UBT) and stool antigen research (STR), both of which are used to identify diseases.
Another important factor influencing the market is the requirement for effective anti-microbial treatment. There is a need for more research to truly understand the effectiveness of non-invasive diagnostic tests because each test has a different range of sensitivity and specificity. The market is growing as a result of advancements in laboratory serological assay.
As the risk of helicobacter pylori infection rises with age, the prevalence of gastric disease is noticeably higher in the elderly population. Age-related stomach lining loss makes it easier for bacteria to pass across the barrier, which helps explain why infections are becoming more common in older people. The global demand for primary care services is rising as a result of the increasing geriatric population. This boosts the need for diagnostics around the world, which is fueling market expansion.
“Increasing Adoption of Point-of-care Testing Techniques”
Many clinicians see point-of-care (POC) testing as essential for the early detection of life-threatening circumstances because the results can be made available in real time. The adoption of point-of-care diagnostics and monitoring equipment is expected to increase in homes, medical offices, and hospitals.
Top competitors in the market are constantly introducing new POCT technologies, which have increased public testing as well as the variety of clinical applications that are readily available. Additionally, POCT is routinely used in all hospitals and is evolving into the gold standard for patient care in a variety of healthcare settings.
Therefore, the market is projected to have profitable growth prospects over the coming years due to an increase in different initiatives to raise awareness among people about the diagnosis of helicobacter pylori and the growing use of POC testing techniques globally.
What Could Possibly Hinder Helicobacter Pylori Non-Invasive Testing Demand?
“Strict Regulatory Standards and Lack of Qualified Specialists”
It is anticipated that the market will be hampered by low diagnostic rates, the asymptomatic nature of the infection, and strict regulatory standards. A shortage of qualified specialists in many low- and middle-income economies with limited healthcare resources is hampering market growth.
Which Region Holds a Leading Position in the Global Helicobacter Pylori Non-Invasive Testing Market?
“Government Efforts to Reduce H. pylori Infection Rates Driving Market Value in North America”
North America accounts for 50% share of the global market owing to changing healthcare reforms and the implementation of guidelines by healthcare agencies regarding helicobacter pylori non-invasive testing. These policies have redirected healthcare organizations and professionals to concentrate more on urea breath tests.
Government efforts to reduce H. pylori infection rates and an increase in the local supply of modern helicobacter pylori non-invasive testing devices are driving market growth in the region.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
How is the United States Complementing North American Market Growth?
“High Awareness of Infectious Disease Detection & Treatment”
The market in the United States is anticipated to experience rapid growth due to the implementation of helicobacter pylori non-invasive testing techniques by healthcare facilities. Rising awareness of infectious disease detection and treatment and the introduction of new products are all contributing to market growth.
Why Does Germany Account for a Leading Position in Europe?
“Increasing Adoption of Stool Antigen Tests in Germany”
The presence of major companies and rapid innovations in helicobacter pylori non-invasive testing systems are driving market growth in Germany. Increasing adoption of stool antigen tests is boosting market value in the country.
Will Japan Emerge as a Lucrative Market for Helicobacter Pylori Non-Invasive Testing?
“Growing Prevalence of Gastrointestinal Disorders”
The rapidly expanding pharmaceutical industry, increasing prevalence of gastrointestinal disorders, and rising geriatric population are driving market growth in Japan. An increase in disposable income, a growing medical tourism industry, and improved infrastructure facilities for diagnostic purposes are the elements fueling market revenue in Japan.
Category-wise Insights
Why is Demand for Urea Breath Tests Increasing Rapidly?
“Urea Breath Tests Gaining Traction Due to Their Excellent Clinical Sensitivity and High Accuracy in Detecting H. pylori”
Based on non-invasive test types, the market is divided into serology tests, urea breath tests, and stool antigen tests. Urea breath tests account for 50% share of the global market.
Excellent clinical sensitivity and high accuracy in detecting helicobacter pylori are anticipated to boost the demand for urea breath tests. Urea breath tests are non-invasive, precise, and safe for both pregnant women and young patients. Urea breath tests are also useful for the evaluation of post-treatment status.
Non-invasive urea breath tests are used to determine whether the digestive system has the helicobacter pylori bacterium. The effectiveness of helicobacter pylori infection treatment can also be determined using this method. A helicobacter pylori bacterium can attack the duodenum and stomach.
Which End User is Predicted to Gain a Prominent Market Share?
“Hospitals Most Popular Due to Their Excellent Quality of Care at Reasonable Costs”
The market is divided into hospitals, diagnostic labs, and clinics based on end user. Hospitals are gaining traction due to the availability of skilled specialists, and the increasing occurrence of conditions such as duodenal ulcers, stomach cancer, gastritis, and gastric ulcers, as well as infections of the small intestine.
The demand for helicobacter pylori non-invasive testing in hospitals is anticipated to be driven by a rise in healthcare spending as well as an increase in patients visiting hospitals due to gastric cancer. Hospitals tend to attract more patients since they provide high-quality care and promptly address patients' requirements, resulting in successful treatments at reasonable costs. The premium services offered by hospitals as a result of effective illness management strategies are driving market expansion.
Competitive Landscape
The market is expected to develop due to an increase in product approvals. Leading companies are focusing on quality control, pricing trends, technological innovations, and supply chain management. They are enhancing product standards and introducing advanced helicobacter pylori non-invasive testing techniques following safety regulations to lower the environmental impact.
For instance :
- Meridian Bioscience, Inc. offers its tests and assay kits to hospitals, reference laboratories, and other diagnostic manufacturers in more than 60 countries. Its helicobacter pylori testing products include the Premium Platinum HpSA PLUS or Premium H. Pylori. It is an in vitro qualitative procedure to detect the presence of helicobacter pylori bacteria in human stool.
- Exalenz Biosciences manufactures the H. Pylori IgG ELISA Kit, BreathID HP, BreathID Smart, and Breath ID Lab devices. These devices conduct a quick and accurate Urea Breath Test for diagnosing helicobacter pylori infection and confirming post-treatment eradication. The test is conducted in real-time by continuously sampling breath, eliminating the need for sample collection, labeling, transport, and analysis.
Key Segments of Helicobacter Pylori Non-Invasive Testing Industry Research
-
By Non-invasive Test Type :
- Serology Tests
- Stool Antigen Tests
- Urea Breath Tests
-
By Test Type :
- Laboratory-based Tests
- Point-of-Care Tests
-
By End User :
- Hospitals
- Diagnostic Labs
- Clinics
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Acronyms Used 3. Research Methodology 4. Executive Summary 5. Market Overview 5.1. Test Type Overview 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.3. Global Market Value (US$ Mn) Forecast, 2023-2033 5.4. Global Market Outlook 5.5. Key Industry Developments 5.6. Epidemiological Assessment of Helicobacter Pylori 5.7. New Non-invasive Test launches, by Market Players 5.8. Key Technological Advancements in Diagnostic Testing 6. Global Market Analysis, by Test Type 6.1. Introduction 6.2. Key Findings 6.3. Global Market Value Share Analysis, by Test Type 6.4. Global Market Value Forecast, by Test Type, 2023-2033 6.4.1. Serology Test 6.4.2. Stool Antigen Test (SAT) 6.4.3. Urea Breath Test (UBT) 6.4.4. Endoscopy Test Types 6.5. Global Market Attractiveness, by Test Type, 2023-2033 7. Global Market Analysis, by Test Method 7.1. Introduction 7.2. Key Findings 7.3. Market Value Share Analysis, by Test Method 7.4. Market Value Forecast, by Test Method, 2023-2033 7.4.1. Laboratory-based Tests 7.4.2. Point-of-Care Tests 7.5. Market Attractiveness, by Test Method 8. Global Market Analysis, by End-user 8.1. Introduction 8.2. Key Findings 8.3. Market Value Share Analysis, by End-user 8.4. Market Value Forecast, by End-user, 2023-2033 8.4.1. Hospitals 8.4.2. Clinics 8.4.3. Diagnostic Laboratories 8.5. Market Attractiveness, by End-user 9. Global Market Analysis and Forecasts, by Region 9.1. Introduction 9.2. Regional Outlook 9.3. Global Market Value Forecast, by Region, 2023-2033 9.3.1. North America 9.3.2. Europe 9.3.3. Asia Pacific 9.3.4. Latin America 9.3.5. Middle East & Africa 9.4. Global Market Attractiveness Analysis, by Region 10. North America Market Analysis 10.1. Key Findings 10.2. North America Market Value Forecast, by Country, 2023-2033 10.2.1. U.S. 10.2.2. Canada 10.3. North America Market Value Forecast, by Test Type, 2023-2033 10.3.1. Serology Test 10.3.2. Stool Antigen Test (SAT) 10.3.3. Urea Breath Test (UBT) 10.4. North America Market Value Forecast, by Test Method, 2023-2033 10.4.1. Laboratory-based Tests 10.4.2. Point-of-Care Tests 10.5. North America Market Value Forecast, by End-user, 2023-2033 10.5.1. Hospitals 10.5.2. Clinics 10.5.3. Diagnostic Laboratories 10.6. North America Market Attractiveness Analysis 10.6.1. By Country 10.6.2. By Test Type 10.6.3. By Test Method 10.6.4. By End-user 11. Europe Market Analysis 11.1. Key Findings 11.2. Europe Market Value Forecast by Country/Sub-region, 2023-2033 11.2.1. Germany 11.2.2. U.K. 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Rest of Europe 11.3. Europe Market Value Forecast, by Test Type, 2023-2033 11.3.1. Serology Test 11.3.2. Stool Antigen Test (SAT) 11.3.3. Urea Breath Test (UBT) 11.3.4. Endoscopy Test Types 11.4. Europe Market Value Forecast, by Test Method, 2023-2033 11.4.1. Laboratory-based Tests 11.4.2. Point-of-Care Tests 11.5. Europe Market Value Forecast, by End-user, 2023-2033 11.5.1. Hospitals 11.5.2. Clinics 11.5.3. Diagnostic Laboratories 11.6. Europe Market Attractiveness Analysis 11.6.1. By Country/Sub-region 11.6.2. By Test Type 11.6.3. By Test Method 11.6.4. By End-user 12. Asia Pacific Market Analysis 12.1. Key Findings 12.2. Asia Pacific Market Value Forecast by Country/Sub-region, 2023-2033 12.2.1. China 12.2.2. India 12.2.3. Japan 12.2.4. Australia 12.2.5. Rest of Asia Pacific 12.3. Asia Pacific Market Value Forecast, by Test Type, 2023-2033 12.3.1. Serology Test 12.3.2. Stool Antigen Test (SAT) 12.3.3. Urea Breath Test (UBT) 12.3.4. Endoscopy Test Types 12.4. Asia Pacific Market Value Forecast, by Test Method, 2023-2033 12.4.1. Laboratory-based Tests 12.4.2. Point-of-Care Tests 12.5. Asia Pacific Market Value Forecast, by End-user, 2023-2033 12.5.1. Hospitals 12.5.2. Clinics 12.5.3. Diagnostic Laboratories 12.6. Asia Pacific Market Attractiveness Analysis 12.6.1. By Country/Sub-region 12.6.2. By Test Type 12.6.3. By Test Method 12.6.4. By End-user 13. Latin America Market Analysis 13.1. Key Findings 13.2. Latin America Market Value Forecast by Country/Sub-region, 2023-2033 13.2.1. Brazil 13.2.2. Mexico 13.2.3. Rest of Latin America 13.3. Latin America Market Value Forecast, by Test Type, 2023-2033 13.3.1. Serology Test 13.3.2. Stool Antigen Test (SAT) 13.3.3. Urea Breath Test (UBT) 13.3.4. Endoscopy Test Types 13.4. Latin America Market Value Forecast, by Test Method, 2023-2033 13.4.1. Laboratory-based Tests 13.4.2. Point-of-Care Tests 13.5. Latin America Market Value Forecast, by End-user, 2023-2033 13.5.1. Hospitals 13.5.2. Clinics 13.5.3. Diagnostic Laboratories 13.6. Latin America Market Attractiveness Analysis 13.6.1. By Country/Sub-region 13.6.2. By Test Type 13.6.3. By Test Method 13.6.4. By End-user 14. Middle East & Africa Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Market Value Forecast by Country/Sub-region, 2023-2033 14.2.1. GCC Countries 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of Middle East & Africa 14.3. Middle East & Africa Market Value Forecast, by Test Type, 2023-2033 14.3.1. Serology Test 14.3.2. Stool Antigen Test (SAT) 14.3.3. Urea Breath Test (UBT) 14.3.4. Endoscopy Test Types 14.4. Middle East & Africa Market Value Forecast, by Test Method, 2023-2033 14.4.1. Laboratory-based Tests 14.4.2. Point-of-Care Tests 14.5. Middle East & Africa Market Value Forecast, by End-user, 2023-2033 14.5.1. Hospitals 14.5.2. Clinics 14.5.3. Diagnostic Laboratories 14.6. Middle East & Africa Market Attractiveness Analysis 14.6.1. By Country/Sub-region 14.6.2. By Test Type 14.6.3. By Test Method 14.6.4. By End-user 15. Competitive Landscape 15.1. Competition Matrix 15.2. Market Share Analysis, by Company, 2018 15.3. Company Profiles 15.3.1. DiaSorin S.p.A. 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.1.2. Financial Overview 15.3.1.3. Test Type Portfolio 15.3.1.4. SWOT Analysis 15.3.1.5. Strategic Overview 15.3.2. Meridian Bioscience, Inc. 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2.2. Financial Overview 15.3.2.3. Test Type Portfolio 15.3.2.4. SWOT Analysis 15.3.2.5. Strategic Overview 15.3.3. Exalenz Bioscience Ltd. 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.3.2. Financial Overview 15.3.3.3. Test Type Portfolio 15.3.3.4. SWOT Analysis 15.3.3.5. Strategic Overview 15.3.4. Alere 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.4.2. Financial Overview 15.3.4.3. Test Type Portfolio 15.3.4.4. SWOT Analysis 15.3.4.5. Strategic Overview 15.3.5. Thermo Fisher Scientific 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.5.2. Financial Overview 15.3.5.3. Test Type Portfolio 15.3.5.4. SWOT Analysis 15.3.5.5. Strategic Overview 15.3.6. Biomerica, Inc. 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.6.2. Financial Overview 15.3.6.3. Test Type Portfolio 15.3.6.4. SWOT Analysis 15.3.6.5. Strategic Overview 15.3.7. Certest Biotec S.L. 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.7.2. Financial Overview 15.3.7.3. Test Type Portfolio 15.3.7.4. SWOT Analysis 15.3.7.5. Strategic Overview 15.3.8. Sekisui Diagnostics 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.8.2. Financial Overview 15.3.8.3. Test Type Portfolio 15.3.8.4. SWOT Analysis 15.3.8.5. Strategic Overview 15.3.9. CorisBioconcept SPRL 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.9.2. Financial Overview 15.3.9.3. Test Type Portfolio 15.3.9.4. SWOT Analysis 15.3.9.5. Strategic Overview 15.3.10. Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.10.2. Financial Overview 15.3.10.3. Test Type Portfolio 15.3.10.4. SWOT Analysis 15.3.10.5. Strategic Overview
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Forecast, by Non-invasive Test Type, 2023–2033
Table 02: Global Market Value (US$ Mn) Forecast, by Test Method, 2023–2033
Table 03: Global Market Value (US$ Mn) Forecast, by End User, 2023–2033
Table 04: Global Market Value (US$ Mn) Forecast, by Region, 2023–2033
Table 05: North America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033
Table 06: North America Market Revenue (US$ Mn) Forecast, by Non-invasive Test Type, 2023–2033
Table 07: North America Market Revenue (US$ Mn) Forecast, by Test Method, 2023–2033
Table 08: North America Market Revenue (US$ Mn) Forecast, by End User, 2023–2033
Table 09: Europe Market Revenue (US$ Mn) Forecast, by Country, 2023–2033
Table 10: Europe Market Revenue (US$ Mn) Forecast, by Non-invasive Test Type, 2023–2033
Table 11: Europe Market Revenue (US$ Mn) Forecast, by Test Method, 2023–2033
Table 12: Europe Market Revenue (US$ Mn) Forecast, by End User, 2023–2033
Table 13: Asia Pacific Market Revenue (US$ Mn) Forecast, by Country, 2023–2033
Table 14: Asia Pacific Market Revenue (US$ Mn) Forecast, by Non-invasive Test Type, 2023–2033
Table 15: Asia Pacific Market Revenue (US$ Mn) Forecast, by Test Method, 2023–2033
Table 16: Asia Pacific Market Revenue (US$ Mn) Forecast, by End User, 2023–2033
Table 17: Latin America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033
Table 18: Latin America Market Revenue (US$ Mn) Forecast, by Non-invasive Test Type, 2023–2033
Table 19: Latin America Market Revenue (US$ Mn) Forecast, by Test Method, 2023–2033
Table 20: Latin America Market Revenue (US$ Mn) Forecast, by End User, 2023–2033
Table 21: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country, 2023–2033
Table 22: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Non-invasive Test Type, 2023–2033
Table 23: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Test Method, 2023–2033
Table 24: Middle East & Africa Market Revenue (US$ Mn) Forecast, by End User, 2023–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Prevalence of Helicobacter Pylori, North America, 2022
Figure 02: Prevalence of Helicobacter Pylori, Europe, 2022
Figure 03: Prevalence of Helicobacter Pylori, Asia Pacific, 2022
Figure 04: Prevalence of Helicobacter Pylori, Latin America, 2022
Figure 05: Prevalence of Helicobacter Pylori, Middle East & Africa, 2022
Figure 06: Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Size (US$ Mn) Forecast, 2023–2033
Figure 07: Opportunity Map, by Non-invasive Test Type and Test Method, 2022
Figure 08: Opportunity Map, by End User, 2022
Figure 09: Global Market Value Share, by Region (2022)
Figure 10: Global Market Value Share, by Test Method (2022)
Figure 11: Global Market Value Share, by Non-Invasive Test Type (2022)
Figure 12: Global Market Value Share, by End-user (2022)
Figure 13: Global Market Value Share, by Non-invasive Test Type, 2020 and 2026
Figure 14: Global Market Revenue (US$ Mn), by Serology Test, 2023–2033
Figure 15: Global Market Revenue (US$ Mn), by SAT, 2023–2033
Figure 16: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%), by UBT, 2023–2033
Figure 17: Global Market Attractiveness, by Non-invasive Test Type, 2023–2033
Figure 18: Global Market Value Share, by Test Method, 2020 and 2026
Figure 19: Global Market Attractiveness, by Test Method, 2023–2033
Figure 20: Global Market Revenue (US$ Mn), by Laboratory Based Tests, 2023–2033
Figure 21: Global Market Revenue (US$ Mn), by Point-of-Care Tests, 2023–2033
Figure 22: Global Market Value Share, by End User, 2020 and 2026
Figure 23: Global Market Attractiveness, by End User, 2023–2033
Figure 24: Global Market Revenue (US$ Mn), by Hospitals, 2023–2033
Figure 25: Global Market Revenue (US$ Mn), by Clinics, 2023–2033
Figure 26: Global Market Revenue (US$ Mn), by Diagnostic Labs, 2023–2033
Figure 27: Global Market Value Share (%), by Region, 2020 and 2026
Figure 28: Global Market Attractiveness, by Region, 2023–2033
Figure 29: North America Market Value Share, by Country, 2020 and 2026
Figure 30: North America Market Attractiveness, by Country, 2023–2033
Figure 31: North America Market Value Share, by Non-invasive Test Type, 2020 and 2026
Figure 32: North America Market Attractiveness, by Non-invasive Test Type, 2023–2033
Figure 33: North America Market Value Share, by Test Method, 2020 and 2026
Figure 34: North America Market Attractiveness, by Test Method, 2023–2033
Figure 35: North America Market Value Share, by End User, 2020 and 2026
Figure 36: North America Market Attractiveness, by End User, 2023–2033
Figure 37: Europe Market Value Share, by Country, 2020 and 2026
Figure 38: Europe Market Attractiveness, by Country, 2023–2033
Figure 39: Europe Market Value Share, by Non-invasive Test Type, 2020 and 2026
Figure 40: Europe Market Attractiveness, by Non-invasive Test Type, 2023–2033
Figure 41: Europe Market Value Share, by Test Method, 2020 and 2026
Figure 42: Europe Market Attractiveness, by Test Method, 2023–2033
Figure 43: Europe Market Value Share, by End User, 2020 and 2026
Figure 44: Europe Market Attractiveness, by End User, 2023–2033
Figure 45: Asia Pacific Market Value Share, by Country, 2020 and 2026
Figure 46: Asia Pacific Market Attractiveness, by Country, 2023–2033
Figure 47: Asia Pacific Market Value Share, by Non-invasive Test Type, 2020 and 2026
Figure 48: Asia Pacific Market Attractiveness, by Non-invasive Test Type, 2023–2033
Figure 49: Asia Pacific Market Value Share, by Test Method, 2020 and 2026
Figure 50: Asia Pacific Market Attractiveness, by Test Method, 2023–2033
Figure 51: Asia Pacific Market Value Share, by End User, 2020 and 2026
Figure 52: Asia Pacific Market Attractiveness, by End User, 2023–2033
Figure 53: Latin America Market Value Share, by Country, 2020 and 2026
Figure 54: Latin America Market Attractiveness, by Country, 2023–2033
Figure 55: Latin America Market Value Share, by Non-invasive Test Type, 2020 and 2026
Figure 56: Latin America Market Attractiveness, by Non-invasive Test Type, 2023–2033
Figure 57: Latin America Market Value Share, by Test Method, 2020 and 2026
Figure 58: Latin America Market Attractiveness, by Test Method, 2023–2033
Figure 59: Latin America Market Value Share, by End User, 2020 and 2026
Figure 60: Latin America Market Attractiveness, by End User, 2023–2033
Figure 61: Middle East & Africa Market Value Share, by Country, 2020 and 2026
Figure 62: Middle East & Africa Market Attractiveness, by Country, 2023–2033
Figure 63: Middle East & Africa Market Value Share, by Non-invasive Test Type, 2020 and 2026
Figure 64: Middle East & Africa Market Attractiveness, by Non-invasive Test Type, 2023–2033
Figure 65: Middle East & Africa Market Value Share, by Test Method, 2020 and 2026
Figure 66: Middle East & Africa Market Attractiveness, by Test Method, 2023–2033
Figure 67: Middle East & Africa Market Value Share, by End User, 2020 and 2026
Figure 68: Middle East & Africa Market Attractiveness, by End User, 2023–2033
Figure 69: Global Helicobacter Pylori (H. Pylori) Non-invasive Testing, Company Share Analysis, 2022 (Estimated)
Figure 70: DiaSorin S.p.A Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 71: DiaSorin S.p.A Breakdown of Net Sales (%), by Region, 2022
Figure 72: Meridian Bioscience, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 73: Meridian Bioscience, Inc. Breakdown of Net Sales (%), by Business Segment, 2022
Figure 74: Exalenz Bioscience Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 75: Exalenz Bioscience Ltd. R&D Expenditure (US$ Mn), 2018-2022
Figure 76: Alere (Abbott) Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 77: Alere (Abbott) Breakdown of Net Sales (%), by Business Segment, 2022
Figure 78: Thermo Fisher Scientific Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 79: Thermo Fisher Scientific Breakdown of Net Sales (%), by Business Segment, 2022
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
At what CAGR is the helicobacter pylori non-invasive testing market expected to progress through 2033?
The global helicobacter pylori non-invasive testing market is set to increase at a CAGR of 4.8% through 2033.
What is the current helicobacter pylori non-invasive testing market size?
Global helicobacter pylori non-invasive testing demand is valued at US$ 500 million in 2023.
Which is the most dominant regional market for helicobacter pylori non-invasive testing?
North America accounts for 50% share of the global helicobacter pylori non-invasive testing market.
What is the forecasted size of the helicobacter pylori non-invasive testing market?
The market for helicobacter pylori non-invasive testing is predicted to reach US$ 800 million by 2033.
Which non-invasive test type accounts for a leading market share?
Urea breath tests hold 50% share of the global market.
Helicobacter Pylori Non-Invasive Testing Market